Combined Use of Bacteroides Fragilis and BCAAs on HBsAg Clearance

Recruiting now

Conditions studied: Chronic Hepatitis B

In brief

The goal of this prospective observational study is to determine the effects of concomitant administration of Bacteroides fragilis and Branched-Chain Amino Acids on hepatitis B virus clearance. The primary question it aims to answer is whether this concomitant administration can promote HBV clearance. The study will observe the HBV clearance rate in chronic hepatitis B patients who receive Bacteroides fragilis and BCAA as a supplement to their routine antiviral therapy. For comparison, researchers will compare the clearance rate in this group to that observed in a control group of chronic hepatitis B patients receiving a standard antiviral regimen based on PegIFNα2b and nucleoside analogs.

Key facts

Study ID

NCT07257562

Run by

First Affiliated Hospital of Fujian Medical University

People needed

40

Starts

2025-06-01

Expected to finish

2026-12-01

Last updated by the study team

2025-12-02

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• chronic hepatitis B patients

You may not qualify if…

• patients with malignancies
• patients with other liver diseases
• pregnancy patients

Where it is running

• The First Affiliated Hospital of Fujian Medical University — Fuzhou, Fujian, China (enrolling)

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.